Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

The Department of Health and Human Services plans to cancel contracts and pull funding for some vaccines being developed to ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

In a report released today, Mani Foroohar from Leerink Partners maintained a Sell rating on Moderna, with a price target of $18.00. The company’s shares opened today at $28.20. Take advantage of ...

In addition to Oppenheimer, Moderna also received a Hold from Citi’s Geoff Meacham in a report issued today. However, on the same day, Bank of America Securities reiterated a Sell rating on Moderna ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...

The US Department of Health and Human Services will cancel contracts and withdraw funding for some vaccines, currently under ...

The company posted strong second-quarter results and reaffirmed its guidance for 2025. Enbridge posted EBITDA of C$4.6 ...

The U.S. Department of Health and Human Services said on Tuesday it would wind down mRNA vaccine development activities under ...

Farmacia Moderna wins the 14th edition of the five-a-side football tournament "United against ALS", but what counts most are ...